Literature DB >> 8552387

The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator.

Y Fujimura1, T Ohno, H Siddique, L Lee, V N Rao, E S Reddy.   

Abstract

Molecular characterization of malignant melanoma of soft parts or soft tissue clear cell sarcoma which shares t(12;22) chromosome translocation revealed fusion of EWS with a transcriptional factor gene ATF-1. The EWS gene, which encodes an RNA binding protein, was also shown to be involved in Ewing sarcoma, related primitive neuroectodermal tumors and desmoplastic small round cell tumors. In order to understand the functional role of EWS-ATF-1 chimeric protein in human solid tumors, we have cloned the aberrant human ATF-1 (EWS-ATF-1) cDNA and studied its DNA binding, transcriptional activation properties and compared with normal ATF-1 protein. Our results demonstrate that EWS-ATF-1 binds weakly to DNA in vitro but functions as an efficient constitutive transcriptional activator unlike the normal ATF-1 which needs to be induced with cAMP. Deletion analysis revealed that EWS-fusion domain functions as a regulatory domain for the transcriptional activation properties of EWS-ATF-1 chimeric protein. Deletion of leucine zipper domain results in a loss of transcriptional activation of EWS-ATF-1 chimeric protein suggesting that protein-protein interaction play a role in the transcriptional activation properties of EWS-ATF-1. We demonstrate that EWS-fusion domain negatively regulates the DNA binding activity of EWS-ATF-1 chimeric protein. Therefore replacement of part of the amino-terminal kinase regulatory domain of ATF-1 protein with EWS regulatory domain results in an altered DNA binding, protein-protein interactions and transcriptional activation properties of EWS-ATF-1 causing deregulated gene expression which may be responsible for the genesis of t(12;22) chromosome translocation-bearing human solid tumors. Targeting the transcriptional cofactors (CBP, etc) by EWS-fusion proteins could be one of the mechanisms of activation of EWS-fusion proteins in human neoplasia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8552387

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

3.  Molecular diagnosis of clear cell sarcoma: detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases.

Authors:  Cristina R Antonescu; Sylvia J Tschernyavsky; James M Woodruff; Achim A Jungbluth; Murray F Brennan; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

Review 4.  Targeted therapies for advanced Ewing sarcoma family of tumors.

Authors:  Yunyun Jiang; Joseph Ludwig; Filip Janku
Journal:  Cancer Treat Rev       Date:  2015-03-27       Impact factor: 12.111

Review 5.  BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.

Authors:  C W Wong; Y S Fan; T L Chan; A S W Chan; L C Ho; T K F Ma; S T Yuen; S Y Leung
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

6.  Curent concepts in pathology of soft tissue sarcoma.

Authors:  Nuzhat Husain; Nidhi Verma
Journal:  Indian J Surg Oncol       Date:  2012-04-03

7.  EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice.

Authors:  Kazunari Yamada; Takatoshi Ohno; Hitomi Aoki; Katsunori Semi; Akira Watanabe; Hiroshi Moritake; Shunichi Shiozawa; Takahiro Kunisada; Yukiko Kobayashi; Junya Toguchida; Katsuji Shimizu; Akira Hara; Yasuhiro Yamada
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

8.  Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.

Authors:  Satoru Yokoyama; Erez Feige; Laura L Poling; Carmit Levy; Hans R Widlund; Mehdi Khaled; Andrew L Kung; David E Fisher
Journal:  Pigment Cell Melanoma Res       Date:  2008-06-27       Impact factor: 4.693

Review 9.  TFEB at a glance.

Authors:  Gennaro Napolitano; Andrea Ballabio
Journal:  J Cell Sci       Date:  2016-06-01       Impact factor: 5.285

10.  P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA.

Authors:  Jianfei Zhao; Jason R Stagno; Lyuba Varticovski; Eric Nimako; Vikas Rishi; Kathy McKinnon; Rhone Akee; Robert H Shoemaker; Xinhua Ji; Charles Vinson
Journal:  Mol Pharmacol       Date:  2012-07-31       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.